Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins

Prostate

Volumn 71, Issue 16, 2011, Pages 1810-1817

  Sánchez, Catherine ^a   Mercado, Alejandro ^a,b   Contreras, Héctor R ^a   Mendoza, Patricia ^a   Cabezas, Juan ^b   Acevedo, Cristian ^b   Huidobro, Christian ^b   Castellõn, Enrique A ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

chemotherapeutic drugs; multidrug resistance proteins; primary cell culture; prostate cancer; siRNA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3 AMINOBENZAMIDE; CISPLATIN; CYCLOSPORIN A; DOCETAXEL; GENISTEIN; GLYCOPROTEIN P; LRP PROTEIN; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VERLUKAST;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL SURVIVAL; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHENOTYPE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 80054070911     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21398     Document Type: Article

References (29)

1. AmericanCancerSociety: Cancer facts and figures 2009. Atlanta: American Cancer Society; 2009.
2. Ferlay J, Parkin DM, Steliarova-Foucher E,: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46 (4): 765-781.
3. Vogiatzi P, Cassone M, Claudio L, Claudio PP,. Targeted therapy for advanced prostate cancer: Looking through new lenses. Drug News Perspect 2009; 22 (10): 593-601.
4. Petrylak DP,. The treatment of hormone-refractory prostate cancer: Docetaxel and beyond. Rev Urol 2006; 8 (Suppl. 2): S48-S55.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512. (Pubitemid 39315317)
6. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM,: Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23 (15): 3343-3351.
7. Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM,: Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010; 116 (7): 1699-1708.
8. Stavridi F, Karapanagiotou EM, Syrigos KN,: Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 2010; 36 (2): 122-130.
9. Sanchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C, Castellon EA,: Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 2009; 69 (13): 1448-1459.
10. Fletcher JI, Haber M, Henderson MJ, Norris MD,: ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer 2010; 10 (2): 147-156.
11. Castellon E, Venegas K, Saenz L, Contreras H, Huidobro C,: Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. Int J Androl 2005; 28 (1): 39-46. (Pubitemid 40203731)
12. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,: Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39 (1): 41-51. (Pubitemid 46026500)
13. Gleason DF,: Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50 (3): 125-128.
14. Contreras HR, Ledezma RA, Vergara J, Cifuentes F, Barra C, Cabello P, Gallegos I, Morales B, Huidobro C, Castellon EA,: The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol 2010; 28 (5): 534-540.
15. Collins R, Trowman R, Norman G, Light K, Birtle A, Fenwick E, Palmer S, Riemsma R,: A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br J Cancer 2006; 95 (4): 457-462. (Pubitemid 44232554)
16. Yague E, Raguz S,: Drug resistance in cancer. Br J Cancer 2005; 93 (9): 973-976. (Pubitemid 41548388)
17. Colabufo NA, Pagliarulo V, Berardi F, Contino M, Inglese C, Niso M, Ancona P, Albo G, Pagliarulo A, Perrone R,: Bicalutamide failure in prostate cancer treatment: Involvement of multi drug resistance proteins. Eur J Pharmacol 2008; 601 (1-3): 38-42.
18. Larrivee B, Averill DA,: Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cells: Reversal of resistance by cyclosporin A and hyperthermia. Biochem Pharmacol 1999; 58 (2): 291-302. (Pubitemid 29255948)
19. Morjani H, Madoulet C,: Immunosuppressors as multidrug resistance reversal agents. Methods Mol Biol 2010; 596: 433-446.
20. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH,: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005; 65 (15): 6934-6942. (Pubitemid 41060733)
21. Oza AM,: Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp 2002; 243: 103-115 (discussion 115-108, 180-105).
22. Ponte-Sucre A,: Availability and applications of ATP-binding cassette (ABC) transporter blockers. Appl Microbiol Biotechnol 2007; 76 (2): 279-286. (Pubitemid 47101682)
23. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Tesei A, Silvestrini R, Amadori D, Zoli W,: Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Prostate 2010; 70 (2): 219-227.
24. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J,: Interfering with disease: A progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6 (6): 443-453. (Pubitemid 47064567)
25. Azuma K, Nakashiro K, Sasaki T, Goda H, Onodera J, Tanji N, Yokoyama M, Hamakawa H,: Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells. Biochem Biophys Res Commun 2010; 391 (1): 1075-1079.
26. Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D,: In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005; 11 (12): 4487-4494. (Pubitemid 40825639)
27. Toudjarska I, de Fougerolles A,: Silencing prostate cancer. Nat Biotechnol 2009; 27 (9): 821-823.
28. Ahmed HU, Emberton M,: Is focal therapy the future for prostate cancer? Future Oncol 2010; 6 (2): 261-268.
29. Mullenders J, Bernards R,: Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 2009; 28 (50): 4409-4420.